Belite Bio (BLTE) vs Ionis Pharmaceuticals (IONS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Belite Bio (BLTE) has outperformed Ionis Pharmaceuticals (IONS) over the past year, gaining 101.7% versus a loss of 38.1%. Ionis Pharmaceuticals is the larger company by market cap ($7.20 billion vs $6.14 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLTE | IONS |
|---|---|---|
| Share price | $152.52 | $43.30 |
| Market cap | $6.14B | $7.20B |
| 1-day change | -2.28% | -1.95% |
| YTD return | -2.43% | -45.27% |
| 1-year return | +101.65% | -38.11% |
| 5-year return | — | +23.36% |
| Forward P/E | 67.49 | — |
| EPS (TTM) | $-2.74 | $-3.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $943.71M |
| Revenue growth (YoY) | — | +33.83% |
| Net income (latest FY) | $-77.61M | $-381.39M |
| Gross margin | — | 98.31% |
| Operating margin | — | -40.45% |
| Net margin | — | -40.41% |
| 52-week high | $200.00 | $86.74 |
| 52-week low | $77.13 | $42.63 |
| Distance from 52-week high | -23.74% | -50.08% |
| Analyst consensus | none | buy |
| Avg. price target upside | +50.07% | +93.16% |
| Average volume | 178.90K | 3.78M |
| Shares outstanding | 40.27M | 166.18M |
| Employees | 41 | 1,480 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BLTE has outperformed IONS by 139.8 percentage points over the past year.
About Belite Bio
BLTE stock →Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees
About Ionis Pharmaceuticals
IONS stock →Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).
Health Care · Biotechnology: Pharmaceutical Preparations · 1,480 employees
BLTE vs IONS FAQ
Which is bigger, Belite Bio or Ionis Pharmaceuticals?
Ionis Pharmaceuticals (IONS) is larger, with a market capitalization of $7.20B compared with $6.14B for Belite Bio (BLTE).
Which stock has performed better over the past year, BLTE or IONS?
BLTE returned +101.65% over the past 12 months, compared with -38.11% for IONS (price return, excluding dividends). Past performance does not predict future results.
Are Belite Bio and Ionis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.